Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.44 |
| ▸ | MME | P08473 | 3/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30628704 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL4811341 | 0.85 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL4811726 | 0.85 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL6309635 | 0.85 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL2555309 | 0.82 | MME (0.43) | MMEACECPA1ACE2LTA4H | |
| SCHEMBL2555307 | 0.82 | MME (0.43) | MMEACECPA1ACE2LTA4H | |
| SCHEMBL15123452 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL15123451 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL29540482 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL10076082 | 0.80 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1MAPTFAAHMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11841369-B2 | Method for improving quality of therapeutic cell through real-time glutathione measurement | CELL2IN, INC. (KR) | 2023-12-12 | — | — | US | claimed |
| CN-111480080-B | Method for improving therapeutic cell quality by real-time glutathione measurement | 塞尔吐温株式会社 | 2023-09-19 | — | — | CN | claimed |
| CN-111492248-B | Method for measuring therapeutic cell mass by real-time glutathione assay | 塞尔吐温株式会社 | 2023-09-12 | — | — | CN | claimed |
| US-11498979-B2 | Methods for preparing a purified maytansinoid conjugate in a solution | IMMUNOGEN, INC. (US) | 2022-11-15 | — | — | US | claimed |
| US-11499978-B2 | Method for measuring quality of therapeutic cell through real-time glutathione measurement | CELL2IN, INC. (KR) | 2022-11-15 | — | — | US | claimed |
| US-20210163625-A1 | CONJUGATION METHODS | IMMUNOGEN SWITZERLAND GMBH (CH) | 2021-06-03 | — | — | US | claimed |
| US-20210003582-A1 | Method for Improving Quality of Therapeutic Cell Through Real-Time Glutathione Measurement | CELL2IN, INC. (KR) | 2021-01-07 | — | — | US | claimed |
| US-20200363422-A1 | Method for Measuring Quality of Therapeutic Cell Through Real-Time Glutathione Measurement | CELL2IN, INC. (KR) | 2020-11-19 | — | — | US | claimed |
| US-10815309-B2 | Methods for preparing antibody-drug conjugates | IMMUNOGEN, INC. (US) | 2020-10-27 | — | — | US | claimed |
| EP-3719501-A1 | METHOD FOR MEASURING QUALITY OF THERAPEUTIC CELL THROUGH REAL-TIME GLUTATHIONE MEASUREMENT | Cell2in, Inc. (KR) | 2020-10-07 | — | — | EP | claimed |
| EP-2903450-A1 | USE OF AN ION EXCHANGE MEMBRANE TO REMOVE IMPURITIES FROM CELL-BINDING AGENT CYTOTOXIC AGENT CONJUGATES | ImmunoGen, Inc. (US) | 2015-08-12 | — | — | EP | claimed |
| US-20140309406-A1 | PREPARATION OF MAYTANSINOID ANTIBODY CONJUGATES BY A ONE-STEP PROCESS | IMMUNOGEN, INC. | 2014-10-16 | — | — | US | claimed |
| US-8795673-B2 | Preparation of maytansinoid antibody conjugates by a one-step process | IMMUNOGEN, INC. (US) | 2014-08-05 | — | — | US | claimed |
| US-20140179906-A1 | CONJUGATION METHODS | IMMUNOGEN, INC. (US) | 2014-06-26 | — | — | US | claimed |
| WO-2014055893-A1 | USE OF AN ION EXCHANGE MEMBRANE TO REMOVE IMPURITIES FROM CELL-BINDING AGENT CYTOTOXIC AGENT CONJUGATES | IMMUNOGEN, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| WO-2014055877-A1 | USE OF A PVDF MEMBRANE TO PURIFY CELL-BINDING AGENT CYTOTOXIC AGENT CONJUGATES | IMMUNOGEN, INC. (US) | 2014-04-10 | — | — | WO | claimed |
| EP-2691155-A2 | PREPARATION OF MAYTANSINOID ANTIBODY CONJUGATES BY A ONE-STEP PROCESS | Immunogen, Inc. (US) | 2014-02-05 | — | — | EP | claimed |
| US-8624003-B2 | Methods for preparation of antibody-maytansinoid conjugates | IMMUNOGEN, INC. (US) | 2014-01-07 | — | — | US | claimed |
| WO-2012135517-A2 | PREPARATION OF MAYTANSINOID ANTIBODY CONJUGATES BY A ONE-STEP PROCESS | IMMUNOGEN, INC. (US) | 2012-10-04 | — | — | WO | claimed |
| US-20120253021-A1 | PREPARATION OF MAYTANSINOID ANTIBODY CONJUGATES BY A ONE-STEP PROCESS | IMMUNOGEN, INC. (US) | 2012-10-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179906-A1 | CONJUGATION METHODS | FCGR2A, FCGR3B, CD47 | SMN1; SMN2 3777/4885ALDH1A1 2667/4885MAPT 4305/4885 |
| US-11498979-B2 | Methods for preparing a purified maytansinoid conjugate in a solution | CD69, PAICS, CD47 | SMN1; SMN2 2621/4885ALDH1A1 1688/4885MAPT 4407/4885 |
| US-10815309-B2 | Methods for preparing antibody-drug conjugates | CD47, FCGR2A, FCGR3B | SMN1; SMN2 3191/4885ALDH1A1 1895/4885MAPT 3670/4885 |
| US-20210163625-A1 | CONJUGATION METHODS | FCGR2A, FCGR3B, CD47 | SMN1; SMN2 3778/4885ALDH1A1 2682/4885MAPT 4306/4885 |
| US-11499978-B2 | Method for measuring quality of therapeutic cell through real-time glutathione measurement | GGT1, GSR, GPX1 | SMN1; SMN2 2003/4885ALDH1A1 664/4885MAPT 3287/4885 |
| US-11841369-B2 | Method for improving quality of therapeutic cell through real-time glutathione measurement | GSR, GPX1, GGT1 | SMN1; SMN2 1048/4885ALDH1A1 786/4885MAPT 3274/4885 |
| US-20140309406-A1 | PREPARATION OF MAYTANSINOID ANTIBODY CONJUGATES BY A ONE-STEP PROCESS | CD47, CD22, CLSPN | SMN1; SMN2 2286/4885ALDH1A1 1373/4885MAPT 3678/4885 |
| US-20120253021-A1 | PREPARATION OF MAYTANSINOID ANTIBODY CONJUGATES BY A ONE-STEP PROCESS | CD47, CD22, CLSPN | SMN1; SMN2 2286/4885ALDH1A1 1373/4885MAPT 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.